• Profile
Close

An antibody that targets all four strains of the virus renews hope for effectively treating and preventing dengue

Agency for Science, Technology and Research (A*STAR) Research News Sep 22, 2017

A vaccine candidate that blocks infection and confers protection against all four strains of dengue virus has been uncovered by Katja Fink and Cheng-I Wang from the A*STAR Singapore Immunology Network, in collaboration with colleagues from across the country.

The development of a safe and effective small molecule drug or vaccine against dengue has been elusive, partly due to the complexity of the virus itself. There are four strains or ‘serotypes’ and each produces different immune responses by interacting with antibodies in human blood serum. Fink’s team have been working to develop a therapeutic agent that is effectively a combination of four treatments.

Their first step was to isolate an antibody (SIgN-3C) produced by a naturally-infected dengue patient that is able to bind to all four dengue virus serotypes and prevent their replication in cells. When administered to mice, SIgN-3C reduced blood-virus levels after exposure to any of the four dengue serotypes. If administered before exposure, it conferred protection against infection.

Similar findings were reported with SIgN-3C-LALA, an intentionally mutated version of the antibody that stops antibody?virus complexes from entering cells, thereby preventing enhancement of dengue infection. This phenomenon known as ‘antibody-dependent enhancement’ helps to explain why patients who have been infected by dengue before are more likely to experience severe symptoms when they are infected subsequently by a different serotype. This is a major barrier for developing therapeutic antibodies against dengue virus.

Fink concedes that they were surprised at the efficiency of SIgN-3C-LALA against all four dengue serotypes. “Usually, very potent neutralizing antibodies are specific against one virus serotype, while cross-reactive antibodies are usually less potent” she explained. The key to this cross-reactivity lies in the unique virus?antibody binding site. SIgN-3C-LALA targets a site that is conserved across serotypes and is crucial for virus integrity.

With a grant from the Global Health Innovative Technology Fund, the team continues to investigate the mechanism of action of the antibody and are working with Chugai Pharmaceuticals to evaluate its suitability for the treatment of dengue in humans.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay